The Methodology of the Collection of Adverse Event Data in Clinical Trials

  • M. D. B. Stephens


In order to collect ADR efficiently, it is necessary to know which factors might hinder their collection so that these can be circumvented. Between the advent of an adverse event and its final assessment as an ADR the adverse event must be communicated. The factors preventing this communication are as follows.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 81.
    Petrie, W.M. and Levine, J. The assessment of adverse reactions in clinical trials. Int Pharmacopsychiat., 1978, 13, 209–216Google Scholar
  2. 82.
    Inman, W.H.W. The United Kingdom. In Monitoring for Drug Safety, MTP Press, Lancaster, 1986Google Scholar
  3. 83.
    Gau, D.W. and Diehl, A.K. Disagreement among general practitioners regarding cause of death. Br. Med. J., 1982, 284, 239–242CrossRefGoogle Scholar
  4. 84.
    Cameron, H.M. and McGregor, E. Prospective study of 1152 hospital autopsies, 1: Inaccuracies in death certification. J. Pathol., 1981, 133, 273–283CrossRefGoogle Scholar
  5. 85.
    Lasagna, L. Techniques for A.D.R. reporting: In Detection and Prevention of Adverse Drug Reactions (ed. H. Böstrom and N. Ljungstedt). Almqvist and Wiksell International Stockholm, 1984, p. 146Google Scholar
  6. 86.
    Harlow, B.J. Monitoring of adverse reactions by a pharmaceutical company before marketing. In Adverse Drug Reactions (ed. D.J. Richards and R.K. Rondel), Churchill Livingstone, 1972Google Scholar
  7. 87.
    Downing, R.W., Rickels, K. and Meyers, F. Side reactions in neurotics, I: A comparison of two methods of assessment. J. Clin. Pharmacol., 1970, 10, Sept–Oct, 289–297Google Scholar
  8. 88.
    Bulpitt, C.J. Randomised Controlled Clinical Trials, Martinus Nijhoff, The Hague, 1983CrossRefGoogle Scholar
  9. 89.
    Bulpitt, C.J., Dollery, C.T. and Carne, S. A symptom questionnaire for hypertensive patients. J. Chron. Dis., 1974, 27, 309–323CrossRefGoogle Scholar
  10. 90.
    Howie, J.G.R. and Clark, G.A. Double blind trial of early demethylchlor-tetracycline in minor respiratory illness in general practice. Lancet, 1970, 2, 1099–1102CrossRefGoogle Scholar
  11. 91.
    Fisher, S., Bryant, S.G. and Kluge, R.M. Measuring ADR in a P.M.S. system Psychopharmacology Bulletin, 22(1), 1986, 272–277Google Scholar
  12. 92.
    Ciccolunghi, S.N. and Chaudri, H.A. A methodological study of some factors influencing the reporting of symptoms. J. Clin. Pharmacol., 1975, 10, July, 496–505CrossRefGoogle Scholar
  13. 93.
    Rickeis, K. and Downing, R.W. Side reactions in neurotics. II. Can patients judge which symptoms are caused by their medication? J. Clin. Pharmacol., 1970, 10, Sept–Oct, 298–305Google Scholar
  14. 94.
    Lapierre, Y.D. Evaluation des effets secondaires chez les neurotiques. Un essai avec les mesoridazin et le placebo. Can. Psychiat. Ass. J., 1975, 26, 61–66Google Scholar
  15. *95.
    Huskisson, E.C. and Wojtulewski, J.A. Measurement of side effects of drugs. Br. Med. J., 1974, 2, 698–699CrossRefGoogle Scholar
  16. 96.
    Bond, A. and Lader, M. The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol., 1974, 47, 211–218CrossRefGoogle Scholar
  17. 97.
    Aitken, R.C.B. Measurement of feelings using analogue scales. Proc. R. Soc. Med., 1969, 62, 989–993Google Scholar
  18. 98.
    Huskisson, E.C. Assessment for clinical trials. Clin. Rheumat. Dis., 1976, 2(1), 37–49Google Scholar
  19. 99.
    Lewis, R.V., Jackson, P.R. and Ramsay, L.E. Measuring side-effects of β-adrenoceptor antagonists: a comparison of two methods Br. J. Clin. Pharmac., 1985, 19, 826–828CrossRefGoogle Scholar
  20. 100.
    Yuen, W.C., Peck, A.W. and Burke, C.A. The subjective effects of dextromethorphan, codeine and diazepam in healthy volunteers. Proceedings of the B.P.S. 10–12 April 1985, p. 290PGoogle Scholar
  21. 101.
    Lundberg, P.K. Assessment of drugs’ side effects: visual analogue scale versus checklist format. Perceptual and Motor Skills, 1980 50, 1067–1073CrossRefGoogle Scholar
  22. 102.
    Lewis, R.V., Jackson, P.R. and Ramsay, L.E. Measuring Beta-adrenocep-tor blocker side effects by visual analogue scales: reproducibity of scoring. Proceedings of the B.P.S. 10–12 April 1985, p. 275PGoogle Scholar
  23. 103.
    Talwalker, S. Index of utility and ranking of drugs. Clin. Trial J., 1981, 18(4), 217–224Google Scholar
  24. 104.
    Maxwell, C. Sensitivity and accuracy of the visual analogue scale: a psycho-physical classroom experiment. Br. J. Clin. Pharmac., 1978, 6, 15–24CrossRefGoogle Scholar
  25. 105.
    Parrott, A.C. and Hindmarch, I. Factor analysis of a sleep evaluation questionnaire. Psychological Med., 1978 8, 325–329CrossRefGoogle Scholar
  26. 106.
    McGavin, C.R., Artvinli, M., Naoe, H., McHardy, G.J.R. Dyspnoea, disability and distance walked: comparison of estimates of exercise performance in respiratory disease. Br. Med. J., 1978, 2, 241–243CrossRefGoogle Scholar
  27. 107.
    Aitken, R.C.B. A growing edge of measurement of feelings. Proc. Roy. Soc. Med., 1969, 62, 989–993Google Scholar
  28. 108.
    Zealley, A.K. and Aitken, R.C.B. Measurement of mood. Proc. R. Soc. Med., 1969, 62, 993–996Google Scholar
  29. 109.
    Lewis, R.V., Jackson, P.R. and Ramsay, L.E. Quantification of side effects of Beta-adrenoceptor blockers using visual analogue scales. Br. J. Clin. Pharmac., 1984, 18, 325–330CrossRefGoogle Scholar
  30. 110.
    Chisholm, E.M., de Dombal, F.T., Giles, G.R. Validation of a self-administered questionnaire to elicit gastrointestinal symptoms. Br. Med. J., 1985, 290, 1795–1796CrossRefGoogle Scholar
  31. 111.
    Borghi, C., Pallavini, G., Comi, D., Grillo, G., Lombardo, M., Mantero, O., Minetti, L., Selvini, A. and Suppa, G. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy. Int. J. Clin. Pharmac. Ther. Tox., 1984, 22(6), 324–328Google Scholar
  32. 112.
    Croog, S.H., Levine, S., Testa, M.A., Brown, B., Bulpitt, C.J., Jenkins, D., Klerman, G.L. and Williams, G.H. The effects of antihypertensive therapy in the quality of life. New Engl. J. Med., 1986, 314, 1657–1664CrossRefGoogle Scholar
  33. 113.
    ECDEU Assessment manual (1976 revision) U.S. Department of Health, Education and Welfare. Public Health Service. Alcohol, drug abuse and mental health AdministrationGoogle Scholar
  34. 114.
    Hamilton, M.A. A rating scale for depression. J. Neurol. Neurosurg. Psychiat., 1960, 23, 56CrossRefGoogle Scholar
  35. 115.
    Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J. An inventory for measuring depression. Arch. Gen. Psychiatry, 1961, 4, 561–571CrossRefGoogle Scholar
  36. 116.
    Levine, J. and Schooler, N.R. SAFTEE A technique for the systematic assessment of side effects in clinical trials. Psychopharmacology Bulletin, 1986, 22(2), 343–381Google Scholar
  37. 117.
    Levine, J. Pharmacology and Somatic Treatments Research Branch. N.I.M.H. 5600 Fishers Lane Room 10-f-06. Rockville, Maryland, 20857, USAGoogle Scholar
  38. 118.
    Guy, W., Wilson, W.H., Brooking, B., Manov, G., Fjetland, O. Reliability and validity of SAFTEE: Preliminary analyses. Psychopharmacology Bulletin, 1986, 22(2), 397–491Google Scholar
  39. 119.
    Jacobson, A.F., Goldstein, B.J., Dominguez, R.A. and Steinbook, R.M. Interrater agreement and interclass reliability measures of SAFTEE in Psychopharmacological clinical trials. Psychopharmacology Bulletin 1986, 22(2), 382–388Google Scholar
  40. 120.
    Rabkin, J.G. and Markowitz, J.S. Side effect assessment with SAFTEE: Pilot study of the instrument. Psychopharmacology Bulletin, 1986, 22(2), 389–396Google Scholar
  41. 121.
    Fisher, S., Bryant, S.G. and Kluge, R.M. Measuring adverse drug reactions in a postmarketing surveillance system. Psychopharmacology Bulletin, 1986, 22(1), 272–277Google Scholar
  42. 122.
    Woggon, B., Linden, M., Beckmann, H., Krebs, E., Küfferle, B., Muller-Oerlinghausen, B., Pflug, B. and Schied, H.W. The AMDP system in International clinical trials: A double-blind comparison of fluperlapine and haloperidol. Psychopharmacology Bulletin, 1986, 22(1), 47–51Google Scholar
  43. 123.
    Guy, W. and Ban, T.A. The AMDP System. A Manual for Assessment and Documentation in Psychopathology, Springer Verlag, Heidelberg, 1982Google Scholar
  44. 124.
    Andersen, K., Malm, U., Perris, C., Rapp, W. and Román, G. The inter-rater reliability of scales for rating symptoms and side-effects in schizophrenic patients during a drug trial. Act Psychiat. Scand. Suppl., 1974, 249, 38–42CrossRefGoogle Scholar
  45. 125.
    Vinar, O. Scale for rating emergent symptoms in psychiatry DVP. Activ. Nerv., Suppl., 1971, 238–240Google Scholar
  46. 126.
    Fanshel, S. and Bush, J.W., A Health-status index and it’s application to health-services outcomes. Oper. Res., 1970, 18, 1021–1066CrossRefGoogle Scholar
  47. 127.
    Kirshner, B. and Guyatt, G. A methodological framework for assessing health indices. J Chron. Dis., 1985, 38.1, 27–36CrossRefGoogle Scholar
  48. 128.
    Deyo, R.A. Measuring functional outcomes in therapeutic trials for chronic disease. Controlled Clinical Trials, 1984, 5, 223–246CrossRefGoogle Scholar
  49. 129.
    Bulpitt, C.J. Quality of life in hypertensive patients. In Hypertensive Cardiovascular Disease: Pathophysiology and Treatment (ed. A. Amery), Martinus Nijhoff, 1982Google Scholar
  50. 130.
    Bulpitt, C.J. and Fletcher, A.E. Quality of life in hypertensive patients on different antihypertensive treatments: Rationale for methods employed in a multicentre randomized clinical trial. J. Cardiovasc. Pharmacol., 1985, 7, S137–S145CrossRefGoogle Scholar
  51. 131.
    Sengupta, R.P., Chiu, J.S.P. and Brierley, H. Quality of survival following direct surgery for anterior communicating artery aneurysm. J. Neurosurg., 1975, 43, 58–64CrossRefGoogle Scholar
  52. 132.
    Jachuck, S.J., Brierley, H., Jachuck, S. and Willcox, P.M. The effect of hypotensive drugs on the quality of life. J.R. Coll. Gen. Pract., 1982, 32, 103–105Google Scholar
  53. 133.
    Meenan, R.F., Gertman, P.M. Mason, J.H. Measuring health status in arthritis. The Arthritis impact measurement scale. Arthritis and Rheumatism 1980, 23(2), 146–152CrossRefGoogle Scholar
  54. 134.
    Pincus, T., Summey, J.A., Soraci, S.A., Wallston, K.A. and Hummon, N.P. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health assessment questionnaire. Arthritis and Rheumatism, 1983, 26(11), 1346–1353CrossRefGoogle Scholar
  55. 135.
    Paterson, M., Measuring the socio-economic benefits of auranofin. In Measuring the Social Benefits of Medicine (ed. G. Teeling-Smith), Office of Health Economics, 1983, pp. 97–110Google Scholar
  56. 136.
    Liang, M.H., Cullen, K.E., Larson, M.G. Measuring function and health status in rheumatic disease clinical trials. Clinics in Rheumatic disease, 1983, 9(3), 531–539Google Scholar
  57. 137.
    Brooks, R. Health indicators in arthritis. In Measuring the Social Benefits of Medicine (ed. G. Teeling-Smith), Office of Health Economics, 1983, 84–91Google Scholar
  58. 138.
    Selby, P., Measurement of the quality of life after cancer treatment. Br. J. Hosp. Med., 1985, 33(5), 226–271Google Scholar
  59. 139.
    Selby, P., Chapman, J.-A.W., Etazadi-Amoli, J., Dalley, D. and Boyd, N.F. The development of a method for assessing the quality of life of cancer patients. Br. J. Cancer, 1984, 50, 13–22CrossRefGoogle Scholar
  60. 140.
    Clark, A. and Fallowfield, L.J. Quality of life measurements in patients with malignant disease: a review. J.R. Soc. Med, 1986, 79, 165–168Google Scholar
  61. 141.
    Fletcher, A.E. Bulpitt, C.J. Assessment of quality of life in cardiovascular therapy. Br. J. Clin. Pharmac., 1986, 21, 173S–181SCrossRefGoogle Scholar
  62. 142.
    Guyatt, G.H., Thompson, P.J., Berman, L.B., Sullivan, M.J., Townsend, M., Jones, N.L., Pugsley, S.O. How should we measure function in patients with chronic heart and lung disease. J. Chron. Dis., 38, 1985, 6, 517–524CrossRefGoogle Scholar
  63. 143.
    Guyatt, G.H. The questionnaire in the assessment of cardio-respiratory disease. The McMaster approach. An ICI publication of a workshop held in April 1984 on the assessment of the effect of drug therapy on the quality of life in cardiorespiratory disease.Google Scholar
  64. 144.
    Guyatt, G.H., Berman, L.B., Townsend, M. and Wayne Taylor, D. Should study subjects see their previous responses. J. Chron. Dis., 1985, 38, 12, 1003–1007CrossRefGoogle Scholar
  65. *145.
    Guyatt, G.H., Bombardier, C. and Tugwell, P.X. Measuring disease-specific quality of life in clinical trials. C.M.A.J., 1986, 134, 889–894Google Scholar
  66. 146.
    Avery, C.W., Bertram, P.I., Allison, B. and Mandell, N. Systematic errors in the evaluation of side effects. Am. J. Psychiat., 1967, 123, 875–878CrossRefGoogle Scholar
  67. 147.
    Doẅing, R.W., Rickeis, K. and Meyers, F. Side reactions in neurotics: a comparison of two methods of assessment. J. Clin. Pharmacol., 1970, Sept–Oct., 289–297Google Scholar
  68. 148.
    Lasagna, L. Bias in the elucidation of subjective side effects. Br. J. Clin. Pharmacol., 1981, 11, 111S–113SGoogle Scholar
  69. 149.
    New Zealand Hypertension Study Group. A multicentre open trial of labetalol in New Zealand. Br. J. Clin. Pharmacol., 1979, 179S–182SGoogle Scholar

Copyright information

© M.D.B. Stephens 1988

Authors and Affiliations

  • M. D. B. Stephens

There are no affiliations available

Personalised recommendations